

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 3)*

Alexion Pharmaceuticals

(Name of Issuer)

Common Stock

(Title of Class of Securities)

015351109

(CUSIP Number)
12/31/2004

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- ☒ Rule 13d-1(b)
☐ Rule 13d-1(c)
☐ Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No.: 015351109

1. Names of Reporting Persons
IRS Identification No:

OppenheimerFunds, Inc.
IRS No. 13-2527171

2. Check the Appropriate Box if a Member of a Group (See Instructions):
Joint Filing

3. SEC Use Only

4. Citizenship or Place of Organization:
Colorado

Number of

Shares
Beneficially
Owned by
Each
Reporting
Person With

5. Sole Voting Power:
0

6. Shared Voting Power:
0

7. Sole Dispositive Power:
0

8. Shared Dispositive Power:
2,518,400

9. Aggregate Amount Beneficially Owned by Each Reporting Person:
2,518,400 (beneficial ownership disclaimed pursuant to Rule 13d-4 of the
Exchange Act of 1934)

10. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See
Instructions)
[]

11. Percent of Class Represented by Amount in Row (11):
9.12%

12. Type of Reporting Person (See Instructions):
IA

CUSIP No.: 015351109

1. Names of Reporting Persons
IRS Identification No: 93-1036175

Oppenheimer Global Opportunities Fund

2. Check the Appropriate Box if a Member of a Group (See Instructions):
Joint Filing

3. SEC Use Only

4. Citizenship or Place of Organization:
Massachusetts

Number of
Shares 5. Sole Voting Power:
Beneficially 2,500,000
Owned by
Each
Reporting
Person With

6. Shared Voting Power:
0

7. Sole Dispositive Power:
0

8. Shared Dispositive Power:
2,500,000

9. Aggregate Amount Beneficially Owned by Each Reporting Person:
2,500,000

10. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See
Instructions)
[]

11. Percent of Class Represented by Amount in Row (11):
9.05%

12. Type of Reporting Person (See Instructions):
IV

Item:

1(a) Name of Issuer:
Alexion Pharmaceuticals

1(b) Address of Issuer's Principal Executive Offices:
352 Knotter Drive
Cheshire, CT 06410

2(a) Name of Person Filing:
(i) OppenheimerFunds, Inc.
(ii) Oppenheimer Global Opportunities Fund

2(b) Address of Principal Business Office or, if none, Residence:
(i) Two World Financial Center
225 Liberty Street, 11th Floor
New York, NY 10281-1008
(ii) 6803 S. Tucson Way

2(c) Citizenship:
(i) Colorado
(ii) Massachusetts

2(d) Title of Class of Securities:
Common Stock

2(e) CUSIP Number:
015351109

3 If this statement is filed pursuant to ss.240.13d-1(b) or ss.240.13d-2(b) or (c), check whether the person filing is a:
☒ An investment adviser in accordance with ss.240.13d-1(b)(1)(ii)(E)
☒ Investment company registered under section 8 of the Investment Company Act of 1940
(15 U.S.C. 80a-8)

4(a) Amount beneficially owned:
(i) 2,518,400 (beneficial ownership disclaimed pursuant to Rule 13d-4 of the Exchange Act of 1934)
(ii) 2,500,000

4(b) Percent of class:
(i) 9.12% (reflects ownership reported in 4(b)(ii) below)
(ii) 9.05%

4(c) Number of shares as to which the person has:

- (i) Sole power to vote or to direct the vote:
 - (a) 0
 - (b) 2,500,000
- (ii) Shared power to vote or to direct the vote:
 - (a) 0
 - (b) 0
- (iii) Sole power to dispose or to direct the disposition of:
 - (a) 0
 - (b) 0
- (iv) Shared power to dispose or to direct the disposition of:
 - (a) 2,518,400
 - (b) 2,500,000

5. Ownership of Five Percent or Less of a Class: []

6. Ownership of More than Five Percent on Behalf of Another Person.:
See Exhibit A hereto.

7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:
N/A

8. Identification and Classification of Members of the Group:
N/A

9. Notice of Dissolution of Group:
N/A

-
10. Certification:
By signing below I certify that, to the best of my knowledge and belief,
the securities referred to above were acquired and are held in the
ordinary course of business and were not acquired and are not held for
the purpose of or with the effect of changing or influencing the control
of the issuer of the securities and were not acquired and are not held
in connection with or as a participant in any transaction having that
purpose or effect.
-

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the
information set forth in this statement is true, complete and correct.

02/15/2005
Date

/s/ Mark Vandehey
Signature

Mark Vandehey, Senior Vice President
Chief Compliance Officer
Name/Title

EXHIBIT A

The respective Boards of Directors or Trustees of the registered investment companies
managed by OppenheimerFunds, Inc. ("OFI") that own shares of the issuer can direct the
disposition of dividends received by such funds and can dispose of such securities.
Additionally, OFI shares the power to dispose of such securities with the Board of
Directors or Trustees of such funds; however, the Boards of Directors or Trustees of such
funds have delegated this responsibility to OFI as the funds' investment advisor under the
respective investment advisory agreements. OFI has an interest relating to five (5%)
percent or more of such securities as disclosed on Page 2 hereof, by virtue of the interest
of five percent (5%) or more of such securities by Oppenheimer Global Opportunities Fund as
disclosed on pages 3 and 4 hereof. OFI disclaims ownership of such securities, except as
expressly stated herein.

EXHIBIT B

The undersigned investment company hereby acknowledges and agrees that a report on
Schedule 13G filed by OppenheimerFunds, Inc. on or about the date hereof, relating to the
common stock of Alexion Pharmaceuticals is filed on behalf of the undersigned.

Dated: February 15, 2005

Oppenheimer Global Opportunities Fund

By: /s/ Kathleen T. Ives

Kathleen T. Ives
Assistant Secretary

alexion pharmaceuticals a3 13g(123104).rtf